Vivek Ra­maswamy launch­es bid for US pres­i­den­cy, re­signs from Roivant board

It’s of­fi­cial: Vivek Ra­maswamy is run­ning for US pres­i­dent.

Ra­maswamy may have brand­ed him­self in re­cent months as a cru­sad­er against the “woke agen­da” in cor­po­rate cul­ture, blast­ing some in­vest­ment firms’ fo­cus on en­vi­ron­ment, so­cial and gov­er­nance goals. But in the biotech world, his rep­u­ta­tion is tied to Roivant Sci­ences — the um­brel­la com­pa­ny from which a stream of new com­pa­nies with the “Vant” suf­fix emerged — and the top-dol­lar deals he’s ne­go­ti­at­ed there.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER